MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
0.6601
-0.0382
-5.47%
After Hours: 0.6931 +0.033 +5.00% 17:08 01/17 EST
OPEN
0.6810
PREV CLOSE
0.6983
HIGH
0.7135
LOW
0.6525
VOLUME
571.60K
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
0.5809
MARKET CAP
83.30M
P/E (TTM)
-0.8349
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KPTI last week (0113-0117)?
Weekly Report · 7h ago
Karyopharm Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
Benzinga · 5d ago
Edward White Recommends ‘Buy’ on Karyopharm Therapeutics Amid Promising Outlook and Strategic Developments
TipRanks · 5d ago
Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
TipRanks · 6d ago
Barclays Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)
TipRanks · 6d ago
Karyopharm announces preliminary 2024 revenue
Seeking Alpha · 6d ago
Karyopharm Therapeutics Expects Q4 Revenues Of $30 Mln
NASDAQ · 01/13 14:41
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.